1.2023 Philippine Working Group Consensus Statement on renal denervation therapy for the management of hypertension
Raymond Oliva ; Deborah Ignacia D. Ona ; Lourdes Ella G. Santos ; Felix Eduardo Punzalan ; John David Tan ; Gilbert Villela ; Benjamin Balmores ; Krizia Camille Yap-Uy ; Roberta Maria Cawed-Mende ; Jose Nicholas Cruz
Philippine Journal of Cardiology 2024;52(1):12-18
BACKGROUND
Hypertension is the most common risk factor for cardiovascular disease in the Philippines. Despite the availability of antihypertensive medications that are effective, safe, and tolerated by Filipino patients, the numbers of uncontrolled hypertensives are still increasing. Several factors play in the poor control of blood pressure, particularly resistant hypertension and hyperactive sympathetic nervous system. Renal denervation therapy is a novel device that has been shown to lower blood pressure in patients with resistant and difficult-to-treat hypertension and is deemed safe in clinical trials. A Philippine Working Group composed of specialists in cardiology, hypertension, vascular surgery, and clinical epidemiology has come up with consensus statements in identifying patients who will benefit from the procedure. Locally, there is a need to have hypertension centers treating uncontrolled and resistant hypertension and offer renal denervation therapy to appropriate Filipino patients.
Blood Pressure